For example, in patients, it has been demonstrated that a loading dose of 100 mg of unlabelled cetuximab or panitumumab saturates EGFR expression in normal tissue and, thus, optimizes tumor-to-background contrast subsequently obtained with fluorescently labelled cetuximab or panitumumab 49-51. The gene discussed is EGFR; the disease is neoplasm.